In October 2018, when the U.S. Department of the Treasury announced the new Committee on Foreign Investment in the United States pilot program addressed to critical technologies, it was first perceived by the U.S. biotech industry as a mortar round exploding in a foxhole. Scores of U.S. biotech companies strained amid the dust and rubble to understand the impact of these new rules on their ability to take foreign investment. In a byline article in Law360, partner Rich Matheny explores how CFIUS impacts the biotech industry. Read the article here.